共 36 条
[1]
Wong MCS(2021)Global incidence and mortality of gastric cancer, 1980–2018 JAMA Netw Open 4 27-40
[2]
Huang J(2021)First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial Lancet 398 499-506
[3]
Chan PSF(2022)Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma Int J Clin Pharm 44 895-903
[4]
Janjigian YY(2022)Difference in cost-effectiveness between first-line and third-line or later nivolumab therapy in patients with HER2-negative, unresectable, advanced or recurrent gastric or gastro-esophageal junction cancer in Japan Biol Pharm Bull 45 43-51
[5]
Shitara K(2020)Formal implementation of cost-effectiveness evaluations in japan: a unique health technology assessment System Value Health 23 101-108
[6]
Moehler M(2014)Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial Pharmacoeconomics 32 9-697
[7]
Jiang Y(2012)Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves BMC Med Res Methodol 12 687-719
[8]
Li Y(2010)Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 712-1278
[9]
Wang LXW(2014)Quality of life in the trastuzumab for gastric cancer trial Oncologist 19 1273-247
[10]
Kashiwa M(2011)Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial Br J Cancer 105 234-841